Academic Journal
Molecular markers as possible efficacy predictors of targeted therapy for myelofibrosis: single-center study
| العنوان: | Molecular markers as possible efficacy predictors of targeted therapy for myelofibrosis: single-center study |
|---|---|
| المؤلفون: | O. Yu. Vinogradova, D. I. Shikhbabaeva, Yu. N. Kobzev, A. L. Neverova, M. M. Pankraskina, S. G. Malakho, M. V. Chernikov, M. A. Murzabekova, A. G. Popova, L. B. Egoryan, A. V. Krechetova, V. V. Ptushkin |
| المصدر: | Онкогематология, Vol 18, Iss 4, Pp 115-134 (2023) |
| بيانات النشر: | ABV-press, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Diseases of the blood and blood-forming organs |
| مصطلحات موضوعية: | myelofibrosis, primary myelofibrosis, postpolycythemic myelofibrosis, postthrombocythemic myelofibrosis, jak2v617f, ruxolitinib, myeloproliferative neoplasm, targeted therapy, next generation sequencing, genetics, clinical practice, Diseases of the blood and blood-forming organs, RC633-647.5 |
| الوصف: | Background. Targeted therapy is the most promising in the treatment of myelofibrosis, but it is necessary to search for the reasons limiting its effectiveness. There are known factors negatively affecting the development of myelofibrosis, but data on their negative impact in the context of targeted therapy are scarce.Aim. Assessing the impact of cytogenetic and genetic abnormalities on the course and therapy results for primary and secondary myelofibrosis during ruxolitinib therapy.Materials and methods. The prospective study included 106 patients with myelofibrosis in the chronic phase (53 (50 %) men and 53 (50 %) women) who received ruxolitinib at the Moscow City Hematology Center, S.P. Botkin City Clinical Hospital. The median age of patients was 62 (18–84) years. The median disease duration before initiation of ruxolitinib therapy was 79 (1–432) months. Before therapy, genetic studies were performed, including next-generation sequencing. The median duration of ruxolitinib therapy was 33 (1–111) months. The influence of the cytogenetic landscape, driver mutations, allele burden of JAK2 (over time) and CALR, additional mutations on the dynamics of symptoms, spleen size, achievement of hematological response, overall survival, progression-free survival, survival without blast crisis and without progression of myelofibrosis with targeted therapy was assessed.Results. The studied genetic factors did not have a significant correlation with hemogram parameters. The hematological response in patients with JAK2 and CALR mutations compared favorably with the response in the groups with the MPL mutation and triple negative status (TNS). Higher hematological response rate was obtained in the group with initially low allele burden |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | Russian |
| تدمد: | 1818-8346 2413-4023 |
| Relation: | https://oncohematology.abvpress.ru/ongm/article/view/873; https://doaj.org/toc/1818-8346; https://doaj.org/toc/2413-4023 |
| DOI: | 10.17650/1818-8346-2023-18-4-115-134 |
| URL الوصول: | https://doaj.org/article/acfa0f73165445de81595ace088e5592 |
| رقم الانضمام: | edsdoj.fa0f73165445de81595ace088e5592 |
| قاعدة البيانات: | Directory of Open Access Journals |
| تدمد: | 18188346 24134023 |
|---|---|
| DOI: | 10.17650/1818-8346-2023-18-4-115-134 |